The "middlemen of medicine" have become obstacles to progress, often perpetuating inefficiencies and exacerbating healthcare's existing problems.

Today, Congresswoman Nikki Budzinski (IL-13) hosted a roundtable with independent pharmacists, pharmacy students and faculty ...

Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...

Congresswoman Nikki Budzinski (IL-13) will host a roundtable discussion with independent pharmacists on Saturday, November 2, ...

It remains to be seen how well President Joe Biden’s Inflation Reduction Act will actually work in lowering prescription drug ...

For example, the big-three PBMs are the dominant middlemen in drug transactions, and they’re each part of a company that also owns a top-10 insurer. So they could try to get better deals for their ...

One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...

Donald Trump’s first term as president was characterized by significant turbulence for government healthcare programs. Here’s ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...

Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is ...

“Our inquiry requests information on the factors driving these shortages and scrutinises the practices of opaque drug middlemen.” The three largest wholesalers in the US are Cardinal ...